Recently I had the privilege to talk to him

In the last 25 years, some of baseball’s most memorable moments played out on what proved to be the biggest stage.From dramatic home runs (who can forget Kirk Gibson in 1988 or Joe Carter five years later) to the straight-up weird (we were treated to two in 2003…Steve Bartman in Chicago and the Pedro Martinez throw-down of Don Zimmer), baseball fans have pretty much seen it all.On Oct. Recently, I had the privilege to talk to him.HOVG: You’ve accomplished plenty songwriter, artist, author, filmmaker but I’m cutting right the chase on this one. How did you end up in possession of the “Buckner Ball” It was owned by Charlie Sheen before you got your paws on it, rightRead how Seth ended up with the "Buckner Ball", his fortunate meeting with Mickey Mantle and what baseball team best compares to The Beatles over at The Hall of Very Good .. (NYSE Alternext US:RGN) announced today thatbased on encouraging "Compassionate Use" data showing RGN-259s potentialhealing effects in patients with non-healing corneal ulcers, the company willclose its current double blind, placebo controlled, Phase II clinical trialtargeting a small subset of diabetic patients undergoing vitrectomy (DV) surgeryin order to focus on a patient population with broader market potential. The small proof-of-concept DV trial had been enrolling slowly due to newersurgical procedures that have resulted in a decreasing number of vitrectomyprocedures in the U.S.

where partial removal of the corneal surface is required.The trial has completed patient treatment with the lowest dose of RGN-259. The company estimates it will save approximately $1.8 million infuture costs associated with the DV trial The company is also reporting that Dr. Steven Dunn, the principal investigatorholding the "Compassionate Use" IND, has sought permission from theInstitutional Review Board to expand enrollment to ten patients, allow a longertreatment period if necessary, and include patients with punctate keratitis(numerous small corneal wounds commonly affecting comfort and vision). Thepatients will be evaluated for both corneal healing and improved visual acuity.On November 17, 2008, the company reported that RGN-259 had been used to treatfour patients with non-healing eye ulcers for 28 days with "striking" resultsaccording to Dr Dunn.

"Now that we have seen the clinical activity of RGN-259 in neurotrophickeratopathy patients receiving treatment for their corneal ulcers, we believe itmakes sense to close the diabetic vitrectomy trial and seek to focus on a largercommercial opportunity. About RegeneRx Biopharmaceuticals, Inc.RegeneRx is focused on the discovery and development of novel peptides toaccelerate tissue and organ repair. Currently, RegeneRx is developing threeproduct candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, andcardiovascular tissue repair, respectively. RegeneRx is also developing RGN-457for use in pulmonary indications such as cystic fibrosis. These productcandidates are based on T4, a synthetic copy of a 43-amino acid, naturallyoccurring peptide, in part, under an exclusive world-wide license from theNational Institutes of Health. RegeneRx holds over 60 world-wide patents andpatent applications related to novel peptides and is currently sponsoring threePhase II chronic dermal wound healing clinical trials (one of which was recentlycompleted), a Phase II ophthalmic clinical trial that is the subject of thispress release, and a Phase I parenteral (injectable) clinical trial supportingsystemic delivery of RGN-352 for acute cardiovascular indications.